Navigation Links
China Medical Technologies Reports First Fiscal Quarter Financial Results
Date:8/16/2010

303 Operating margin 27.1% 18.8% 23.3% 23.3% Non-GAAP operating margin 56.8% 53.2% 55.7% 55.7% Net income 191 4,820 33,678 4,966 Adjustments: Stock compensation expense 12,157 10,692 10,592 1,562 Amortization of acquired intangible assets 49,807 49,766 49,743 7,335 Non-cash interest expense of convertible notes 7,620 7,618 7,916 1,167 Non-cash interest expense - amortization of share lending costs(2) 2,756 2,644 2,475 365 Gain on purchase of convertible notes -- (24,064) (47,393) (6,989) Non-GAAP net income 72,531 51,476 57,011 8,406 GAAP net margin 0.1% 2.7% 18.1% 18.1% Non-GAAP net margin 34.7% 29.3% 30.6% 30.6% Net income 191 4,820 33,678 4,966 Adjustments: Interest income (2,773) (4,155) (4,597) (678) Interest expense - convertible notes 35,432 34,831 32,505 4,793 Interest expense - amortization of convertible notes issuance costs 4,380 4,263 4,012 592 Interest expense - amortization of share lending costs(2) 2,756 2,644 2,475 365 Income tax expense 16,919 15,206 18,662 2,752 Depreciation 5,450 5,588 5,475 807 Amortization of acquired intangible assets 49,807 49,766 49,743 7,335 EBITDA 112,162 112,963 141,953 20,932 EBITDA margin 53.7% 64.3% 76.2% 76.2% EBITDA 112,162 112,963 141,953 20,932 Adjustments: Stock compensation expense 12,157 10,692 10,592 1,562 Gain on purchase of convertible notes -- (24,064) (47,393) (6,989) Adjusted EBITDA 124,319 99,591 105,152 15,505 Adjusted EBITDA margin 59.5% 56.7% 56.5% 56.5% Earnings per ADS - basic 0.01 0.19 1.30 0.19 - diluted 0.01 0.19 1.29 0.19 Non-GAAP earnings per ADS - basic 2.76 1.98 2.19 0.32 - diluted(1) 2.74 1.98 2.18 0.32 Weighted average number of ADS - basic 26,324,842 25,993,349 26,005,975 26,005,975 - diluted(1) 26,438,076 26,050,599 26,128,403 26,128,403 Notes: (1) Interest expense and amortization in connection with convertible notes were not added back in computing non-GAAP diluted earnings per ADS because they were anti-dilutive. (2) As a result of the adoption of new authoritative guidance governing the
'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. China Nepstar Chain Drugstore Reports One-time Non-recurring Penalty Payment
2. China Pharma Holdings, Inc. to Report Second Quarter 2010 Financial Results on August 10, 2010
3. Winner Medical Launches Its First Online PurCotton(R) Store in China on Taobao.com
4. FINRA Confirms China BCTs Corporate Name Change
5. China Sky One Medical Obtains SFDA Approval for Ciclopirox Olamine Vaginal Suppositories
6. China Yongxin Pharmaceuticals Inc. Announces the Expansion of Its Chain of Retail Stores to 110 Stores
7. China Nepstar Chain Drugstore Provides Updates on Shoppers Card Program
8. China BCT Announces Auditor Change Within PKF Network
9. China Sky One Medicals Chief Financial Officers Health Issues to Restrict His Availability to Investors
10. China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health
11. MarketsandMarkets: Patient Monitoring Devices Markets in Brazil, Russia, India and China Worth $2,992 Million by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- RnRMarketResearch.com adds Syringes and Needles ... provides an overview of syringes and needles currently ... databases, secondary and primary research. Complete ... spread across 124 pages, talking about 13 companies ... figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
(Date:7/31/2015)... Fla. , July 31, 2015  Xcelience, ... today that it has made a structured cash ... -based company specializing in milling, micronization and powder ... will help grow Powdersize,s business while simultaneously adding ... to Xcelience,s portfolio of capabilities. ...
(Date:7/31/2015)... and SAN DIEGO , July ... parent company Eisai Co., Ltd. (Headquarters: Tokyo ... "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San ... Helen Torley , "NASDAQ: HALO") have signed a clinical ... Halaven ® , "eribulin") in combination with Halozyme,s investigational ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... alvespimycin, the company,s second-generation Hsp90 inhibitor, in,patients with ... to disrupt the activity of multiple oncogenes,and cell ... a,key signaling pathway in breast cancer. The objective ...
... study conducted in MDS - Vidaza therapy confers highly significant 9.4 ... to conventional care regimens, - Two year overall survival rate of 50.8% ... ... Pharmion Corporation,(Nasdaq: PHRM ) today announced the submission of a ...
Cached Medicine Technology:Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 2Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 3Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 2Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 3Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 5Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 6Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 7
(Date:7/31/2015)... ... July 31, 2015 , ... ... been recognized in the 2015 Aster Awards national competition for a marketing communications ... Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. , A ...
(Date:7/31/2015)... ... , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in ... announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a ... MaxLife will grant 100% of the money raised to BioViva to help bring pioneering ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held ... have to. , Instead of risking containment — or even destruction — of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida Hospital Tampa ... that was developed for targeted delivery of fluids to selected sites in the ... Florida Hospital Tampa with the device that provides direct, local delivery of chemotherapy ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National ... Thursday, September 17th at Ford Field in Detroit and the second match will occur ...
Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2
... for years about the health risks of using the Chicago ... Chicago study, canoeing, kayaking, rowing, boating and fishing on the ... performing these same activities on other local waters -- a ... for swimmers at Lake Michigan beaches. The study is ...
... is providing a new route to get to and remove ... natural hole behind the molars, above the jawbone and beneath ... surgery, published in the October the Laryngoscope , the ... faster recovery and fewer complications than traditional approaches. And, because ...
... Oct. 25 (HealthDay News) -- ,Marijuana causes disruptions in ... people with schizophrenia, according to a new study. ... neurons in the brains of rats given a drug ... of marijuana. The effects of the drug on ...
... A new potential leukemia therapy targets only cancer cells, ... treatments affect cancer cells and healthy cells, causing significant ... and depression. This research is being presented at ... Meeting and Exposition in Washington, D.C., Oct. 23 ...
... TUESDAY, Oct. 25 (HealthDay News) -- Scientists have identified mutations ... have a potentially fatal blood clot after undergoing heart stent ... the drug Plavix (clopidogrel), a widely used blood thinner, and ... Oct. 26 issue of the Journal of the American ...
... Sox and Yankee fans alike sitting inches away from the television, ... away It might have been that very moment in 2003 when ... it might have been that very moment in 2004, when Boston,s Pokey ... devastation of 2003 began to fade from the memories of so many ...
Cached Medicine News:Health News:Boaters' risk of illness on Chicago River similar to other waterways 2Health News:Boaters' risk of illness on Chicago River similar to other waterways 3Health News:New 'scarless' surgery takes out tumors through natural skull opening 2Health News:Genes Could Highlight Plavix Users at Clot Risk After Stent 2Health News:A World Series to remember? 2
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
This set includes 2 small, 1 medium, 1 large gonad shields and a belt. The shields and belt is an interchangeable system attached by velcro....
Lap pad used to protect pelvic regions...
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
Medicine Products: